Laura Alder, Thoracic Medical Oncologist at Duke University School of Medicine, shared on X:
“Pivotal DeLLphi305 data Jacob Sands, w/ a phenomenal discussion by Stephen V. Liu w/ two standout quotes:
‘Innovation loses impact if it doesn’t reach the patients who need it most’
‘It is not enough to know if the drugs work or how well they work, we need to know why and in whom they work to make better individualized decisions.’
New standard of care!
- Median OS 21.1 vs 12.7 mo (HR 0.42); 12-mo OS 79.4% vs 53.3%
- 12-mo PFS 38.4% vs 9.5% (HR 0.34)
- Median DOR 12.7 vs 5.6 mo
- No grade ≥3 ICANS; CRS mostly low grade
- Only 1-2 h on-site monitoring after the first 2 doses.”
Title: Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
Auhtors: Maurice Pérol, Tatsuya Yoshida, Myung-Ju Ahn, Carl M. Gay, Martin Schuler, Haifeng Liu, Ahmet Sezer, Ahmet Bilici, Ippokratis Korantzis, Sun Min Lim, Kohei Otsubo, Oscar Juan-Vidal, Yuanbin Chen, Gustavo Schvartsman, Haiyong Wang, Anne-Marie C. Dingemans, Jeffrey M. Clarke, Aakash Desai, Miguel Marigil, Yuqi Chen, Bazle Abidi, Jessie Wang, Jacob Sands.
You can also read: DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
